Real world study of short term efficacy, safety, and tolerability of canagliflozin 100 mg initiation in type 2 diabetes mellitus patients during hot humid Indian summer
- 22 January 2021
- journal article
- research article
- Published by Elsevier BV in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 15 (1), 385-389
- https://doi.org/10.1016/j.dsx.2021.01.011
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesThe New England Journal of Medicine, 2017
- Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysisCardiovascular Diabetology, 2017
- A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitusIndian Journal of Endocrinology and Metabolism, 2017
- Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibitionDiabetologia, 2016
- Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climatesInternational Journal of Clinical Practice, 2016
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic EffectsJournal of the American Society of Nephrology, 2016
- Canagliflozin-Induced Diabetic KetoacidosisJournal of Investigative Medicine High Impact Case Reports, 2016
- Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effectIndian Journal of Endocrinology and Metabolism, 2016
- Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitusJournal of Diabetes and its Complications, 2015
- Canagliflozin: A novel SGLT2 inhibitor for type 2 diabetes mellitusNorth American Journal of Medical Sciences, 2014